BenzamidesPiperazinesPyrimidinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveGastrointestinal Stromal TumorsPregnatrienesFusion Proteins, bcr-ablAntineoplastic AgentsProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaKetonesFuransProtein Kinase InhibitorsLeukemia, Myeloid, Chronic-PhaseReceptor, Platelet-Derived Growth Factor betaHypopigmentationHypereosinophilic SyndromeBlast CrisisCytogenetic AnalysisGenes, ablDrug Resistance, NeoplasmProtein-Tyrosine KinasesErgoloid MesylatesDeferoxamineProto-Oncogene Proteins c-ablGastrointestinal NeoplasmsK562 CellsMesylatesLeukemia, Myeloid, Chronic, Atypical, BCR-ABL NegativePergolidePhiladelphia ChromosomeTreatment OutcomeFenoldopamDrug ApprovalEnzyme InhibitorsRemission InductionPefloxacinBenzoxazinesDelavirdineMastocytosis, SystemicDose-Response Relationship, DrugDermatofibrosarcomaReceptors, Platelet-Derived Growth FactorTubulin ModulatorsPralidoxime CompoundsAdministration, OralQuinolizinesNelfinavirNaphthalenesGabexateFibromatosis, AggressiveProto-Oncogene Proteins c-sisCell Line, TumorAntimitotic AgentsMorpholinesDisease-Free SurvivalPyrrolesCannabinoid Receptor AgonistsErgolinesDihydroergotoxineCannabinoidsLichenoid EruptionsDrug Administration ScheduleApoptosisBromocriptineNauseaHarringtoninesUnited States Food and Drug AdministrationmRNA Cleavage and Polyadenylation FactorsDihydroergotamineTime FactorsPhosphorylationLeukemia, Myeloid, Accelerated PhaseDrug SynergismDoxazosinCell ProliferationRifabutinIndolesInterferon-alphaPrimary MyelofibrosisSurvival AnalysisNeoplasm, ResidualReceptors, GlucocorticoidTreatment FailureVomitingSalvage TherapyCytogeneticsAntineoplastic Combined Chemotherapy ProtocolsPrognosisChromosomes, Human, Pair 9RecurrenceNeutropeniaHistiocytoma, Malignant FibrousDexamethasoneMutationScleroderma, SystemicSTAT5 Transcription FactorThrombocytopeniaDisease ProgressionReceptors, Cannabinoid